One alternative target is the checkpoint molecule B7-H3 (CD276), whose expression has already been associated with PCa progression and worse prognosis [80] and has been suggested as a target for immunotherapy [81, 82]. This evidence concerns the gene CD276 and posterior cortical atrophy.